Windsor Advisory Group LLC cut its stake in Abbott Laboratories (NYSE:ABT – Free Report) by 31.6% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,205 shares of the healthcare product maker’s stock after selling 1,021 shares during the quarter. Windsor Advisory Group LLC’s holdings in Abbott Laboratories were worth $223,000 as of its most recent SEC filing.
Other institutional investors and hedge funds also recently bought and sold shares of the company. Callan Capital LLC increased its stake in Abbott Laboratories by 5.3% in the first quarter. Callan Capital LLC now owns 3,106 shares of the healthcare product maker’s stock worth $315,000 after purchasing an additional 156 shares during the period. Commerzbank Aktiengesellschaft FI purchased a new position in Abbott Laboratories in the 1st quarter worth about $44,004,000. Atomi Financial Group Inc. bought a new stake in shares of Abbott Laboratories during the first quarter valued at approximately $201,000. EP Wealth Advisors LLC bought a new position in Abbott Laboratories in the first quarter worth approximately $5,472,000. Finally, Level Four Advisory Services LLC increased its holdings in Abbott Laboratories by 105.0% during the 1st quarter. Level Four Advisory Services LLC now owns 159,017 shares of the healthcare product maker’s stock worth $16,102,000 after purchasing an additional 81,436 shares during the period. 73.70% of the stock is owned by hedge funds and other institutional investors.
Abbott Laboratories Stock Performance
Shares of Abbott Laboratories stock opened at $102.71 on Thursday. The firm has a market capitalization of $178.24 billion, a P/E ratio of 35.05, a PEG ratio of 4.50 and a beta of 0.68. Abbott Laboratories has a 52 week low of $93.25 and a 52 week high of $115.83. The company has a quick ratio of 1.16, a current ratio of 1.64 and a debt-to-equity ratio of 0.39. The company has a 50 day moving average price of $106.44 and a 200 day moving average price of $105.21.
Insider Buying and Selling
In other Abbott Laboratories news, EVP Andrea F. Wainer sold 10,400 shares of the firm’s stock in a transaction that occurred on Tuesday, August 8th. The shares were sold at an average price of $105.03, for a total transaction of $1,092,312.00. Following the completion of the transaction, the executive vice president now directly owns 65,027 shares of the company’s stock, valued at approximately $6,829,785.81. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In related news, EVP Andrea F. Wainer sold 10,400 shares of the firm’s stock in a transaction on Tuesday, August 8th. The shares were sold at an average price of $105.03, for a total transaction of $1,092,312.00. Following the completion of the transaction, the executive vice president now owns 65,027 shares of the company’s stock, valued at $6,829,785.81. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Daniel J. Starks sold 50,000 shares of the company’s stock in a transaction on Thursday, July 27th. The shares were sold at an average price of $113.76, for a total transaction of $5,688,000.00. Following the completion of the sale, the director now directly owns 6,775,316 shares in the company, valued at $770,759,948.16. The disclosure for this sale can be found here. Corporate insiders own 1.10% of the company’s stock.
Analyst Upgrades and Downgrades
A number of research firms have recently issued reports on ABT. Mizuho increased their price target on Abbott Laboratories from $110.00 to $115.00 and gave the stock a “neutral” rating in a research report on Friday, July 21st. Wolfe Research raised shares of Abbott Laboratories from an “underperform” rating to a “peer perform” rating in a research report on Friday, July 21st. Barclays upped their price target on shares of Abbott Laboratories from $127.00 to $132.00 and gave the stock an “overweight” rating in a research report on Monday, July 24th. StockNews.com began coverage on shares of Abbott Laboratories in a report on Thursday, August 17th. They set a “buy” rating on the stock. Finally, Morgan Stanley restated an “equal weight” rating and set a $112.00 target price on shares of Abbott Laboratories in a report on Friday, July 21st. Five analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $120.82.
Abbott Laboratories Profile
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.
- Five stocks we like better than Abbott Laboratories
- What is a Mid Cap Stock? How to Invest
- 3 Low-Cost ETFs That Are Crushing SPY
- What Does a Stock Split Mean?
- Shutterstock is the Value Stock they don’t want you to know about
- How to Invest in the FAANG Stocks
- Body Slammed Under $100, Is World Wrestling Stock an Opportunity?
Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.